Evidence map›Paper›PMID 40374718›Full record

ArticleScientific reports2025

Electromagnetic waves destabilize the SARS-CoV-2 Spike protein and reduce SARS-CoV-2 Virus-Like particle (SC2-VLP) infectivity.

Christina Pantoja, Francisco M Acosta, Skyler Granatir, Michael Anderson, Maya Wyr, Johann Tailor, Angus Fuori, William Dower, H Bo Marr, Peter W Ramirez

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Christina Pantoja *Department of Biological Sciences, California State University Long Beach, Long Beach, CA, USA.
Francisco M Acosta *Department of Biological Sciences, California State University Long Beach, Long Beach, CA, USA.
Skyler Granatir *Epirus Inc., Torrance, CA, USA.
Michael AndersonDepartment of Biological Sciences, California State University Long Beach, Long Beach, CA, USA.
Maya WyrDepartment of Biological Sciences, California State University Long Beach, Long Beach, CA, USA.
Johann TailorDepartment of Biological Sciences, California State University Long Beach, Long Beach, CA, USA.
Angus FuoriDepartment of Biological Sciences, California State University Long Beach, Long Beach, CA, USA.
William DowerEpirus Inc., Torrance, CA, USA.
H Bo MarrEpirus Inc., Torrance, CA, USA.
Peter W RamirezDepartment of Biological Sciences, California State University Long Beach, Long Beach, CA, USA. Peter.Ramirez@csulb.edu.

Funding

CSULB Building Biomedical Research Program: Overall ComponentUL1GM118979 · NIGMS · CALIFORNIA STATE UNIVERSITY LONG BEACH · PI CHUN, CHI-AH, DILLON, JESSE · 2015 to 2023
$20.7M
CSULB Building Biomedical Research Program: Student Training CoreTL4GM118980 · NIGMS · CALIFORNIA STATE UNIVERSITY LONG BEACH · PI CHUN, CHI-AH, DILLON, JESSE · 2015 to 2023
$12.3M
CSULB Building Biomedical Research Program: Research Enrichment CoreRL5GM118978 · NIGMS · CALIFORNIA STATE UNIVERSITY LONG BEACH · PI CHUN, CHI-AH, DILLON, JESSE · 2015 to 2023
$7.3M
Supplement for CSULB Maximizing Access to Research Careers (MARC) UNDERGRADUATE STUDENT TRAINING IN ACADEMIC RESEARCH (U-STAR)T34GM008074 · NIGMS · CALIFORNIA STATE UNIVERSITY LONG BEACH · PI NARAYANASWAMI, VASANTHY · 1985 to 2022
$4.6M
UC San Diego RAPID Faculty Development Program in Infectious DiseasesR25AI147376 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ADRIANA H TREMOULET, Joann Trejo · 2020 to 2026
$2.5M
Undergraduate Research Training Initiative for Student Enhancement (U-RISE) (T34) at CSULBT34GM149378 · NIGMS · CALIFORNIA STATE UNIVERSITY LONG BEACH · PI VASANTHY NARAYANASWAMI · 2023 to 2026
$2.4M
Bridges to the Doctorate Research Training Program at California State University Long BeachT32GM138075 · NIGMS · CALIFORNIA STATE UNIVERSITY LONG BEACH · PI BRUSSLAN, JUDY ANN, MOTA-BRAVO, LUIS M · 2021 to 2025
$2.1M
Determining the role of AnnexinA2 in HIV-1 and SARS-CoV-2 assemblyR16AI184450 · NIAID · CALIFORNIA STATE UNIVERSITY LONG BEACH · PI PETER William RAMIREZ · 2024 to 2026
$557k
National Institute of Allergy and Infectious Diseases R16AI184450National Science Foundation 2035140NIAID NIH HHS R16 AI184450NIAID NIH HHS R25 AI147376NIGMS NIH HHS RL5 GM118978NIGMS NIH HHS T32 GM138075NIGMS NIH HHS T32GM138075NIGMS NIH HHS T34 GM008074NIGMS NIH HHS T34 GM149378NIGMS NIH HHS T34GM149378NIGMS NIH HHS TL4 GM118980NIGMS NIH HHS TL4GM118980NIGMS NIH HHS UL1 GM118979
6 · The paper itself

Abstract

Infection and transmission of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) continues to pose a global public health concern. Using electromagnetic waves represents an alternative strategy to inactivate pathogenic viruses such as SARS-CoV-2. However, whether electromagnetic waves reduce SARS-CoV-2 infectivity is unclear. Here, we adapted a coplanar waveguide (CPW) to identify frequencies that could potentially neutralize SARS-CoV-2 virus-like particles (SC2-VLPs). Treatment of SC2-VLPs at frequencies between 2.5 and 3.5 GHz and an electric field of 413 V/m reduced infectivity. Exposure of SC2-VLPs to a frequency of 3.1 GHz -and to a lesser extent, 5.9 GHz- reduced their binding to antibodies targeting the SARS-CoV-2 Spike S1 receptor-binding domain (RBD) but did not alter the total levels of Spike, Nucleocapsid, Envelope, or Membrane proteins in virus particles. These results suggest that electromagnetic waves alter the conformation of Spike, thereby reducing viral attachment and entry. Overall, this data provides proof-of-concept in using electromagnetic waves for sanitation and prevention efforts to curb the transmission of SARS-CoV-2 and potentially other pathogenic enveloped viruses.

Indexed as

COVID-19SARS-CoV-2Spike Glycoprotein, CoronavirusAnimalsAntibodies, ViralHumansVero CellsAntibodies, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Coplanar waveguideElectromagnetic wavesSanitationSARS-CoV-2SpikeTransmission

Identifiers

PMID40374718
PMCPMC12081674

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.